Skip to main content
SpringerLink
Log in

Use of Novel Antiplatelet Agents in Acute Coronary Syndromes

  • Coronary Heart Disease (E Gianos and B Shah, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Acute coronary syndromes (ACS) encompass a broad spectrum of clinical presentations based on underlying pathology that results in myocardial ischemia and/or infarction. Despite advancements in invasive management and secondary preventive therapies, recurrent atherothrombotic coronary events remain a prevalent cause of death and recurrent cardiac events after ACS and, in those who survive, the root of long-standing cardiac comorbidities. Antiplatelet drug therapy has proven beneficial in the reduction of these events, and novel antiplatelet agents have resulted in significant improvement in clinical outcomes over the last decade. However, the balance of optimal platelet inhibition with minimal bleeding complications remains a clinical challenge. This review focuses on more recent advances in antiplatelet therapies used in the treatment of ACS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. J Am Coll Cardiol. 2014;64(24):e139–e228. Recently-published consensus guidelines on the management of non-ST segment elevation acute coronary syndromes with updated nomenclature reviewed.

  2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.

    Article  CAS  PubMed  Google Scholar 

  3. Lewis Jr HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396–403.

    Article  PubMed  Google Scholar 

  4. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med. 1984;310:209–14.

    Article  CAS  PubMed  Google Scholar 

  5. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.

    Article  CAS  PubMed  Google Scholar 

  7. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

    Article  CAS  PubMed  Google Scholar 

  8. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667–72.

    Article  CAS  PubMed  Google Scholar 

  9. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators C. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–9.

    Article  CAS  PubMed  Google Scholar 

  10. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J. 2008;156:S16–22.

    Article  PubMed  Google Scholar 

  11. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. The pivotal trial demonstrating benefit of ticagrelor versus clopidogrel in ACS.

    Article  CAS  PubMed  Google Scholar 

  12. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15. The pivotal trial demonstrating benefit of prasugrel compared to clopidogrel in ACS.

    Article  CAS  PubMed  Google Scholar 

  13. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–9.

    Article  CAS  PubMed  Google Scholar 

  14. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33.

    Article  CAS  PubMed  Google Scholar 

  15. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–43. Trial demonstrating benefit of double-dose clopidogrel in ACS but no benefit of double-dose aspirin.

    Article  CAS  PubMed  Google Scholar 

  16. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–51.

    Article  CAS  PubMed  Google Scholar 

  17. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.

    Article  CAS  PubMed  Google Scholar 

  18. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57:1920–59.

    Article  PubMed  Google Scholar 

  19. Chan MY, Mahaffey KW, Sun LJ, et al. Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv. 2008;1:369–78.

    Article  PubMed  Google Scholar 

  20. Solomon MD, Go AS, Shilane D, et al. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;63:2249–57.

    Article  CAS  PubMed  Google Scholar 

  21. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297–309. TRILOGY ACS trial which demonstrated no significant benefit for prasugrel compared to clopidogrel in patients medically managed for ACS.

    Article  CAS  PubMed  Google Scholar 

  22. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35:2083–93. Outcomes demonstrating benefit of ticagrelor as compared to clopidogrel in patients who did and did not undergo percutaneous coronary intervention.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.

    Article  CAS  PubMed  Google Scholar 

  24. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999–1010. The ACCOAST trial demonstrated no benefit of upfront prasugrel compared to placebo prior to PCI in ACS and increased bleeding events.

    Article  CAS  PubMed  Google Scholar 

  25. Montalescot G, von’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016–27.

    Article  CAS  PubMed  Google Scholar 

  26. Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). JACC Cardiovasc Interv. 2010;3:419–27.

    Article  PubMed  Google Scholar 

  27. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009;7:1195–201.

    Article  CAS  PubMed  Google Scholar 

  28. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151:689e1–689e10.

    Article  Google Scholar 

  29. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318–29.

    Article  CAS  PubMed  Google Scholar 

  30. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330–41.

    Article  CAS  PubMed  Google Scholar 

  31. Leonardi S, Truffa AA, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013;99:1282–7.

    Article  CAS  PubMed  Google Scholar 

  32. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182.e4–90.e4.

    Google Scholar 

  33. Thygesen K, Alpert JS, White HD, Joint ESCAAHAWHFTFftRoMI. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173–95.

    Article  PubMed  Google Scholar 

  34. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012;163:768.e2–76.e2.

    Article  Google Scholar 

  35. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–13. The CHAMPION PHOENIX trial demonstrated benefit of cangrelor versus clopidogrel in terms of primary endpoint and stent thrombosis.

    Article  CAS  PubMed  Google Scholar 

  36. Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5:336–46. A novel intravenous antiplatelet therapy demonstrates no significant benefit compared to clopidogrel and increased adverse events.

    Article  CAS  PubMed  Google Scholar 

  37. Neri Serneri GG, Coccheri S, Marubini E, Violi F, Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics Study G. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25:1845–52.

    Article  CAS  PubMed  Google Scholar 

  38. van der Wieken LR, Simoons ML, Laarman GJ, et al. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. Int J Cardiol. 1995;52:125–34.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Michael Luna and Elizabeth M. Holper declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. University of Texas Southwestern School of Medicine, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA

    Michael Luna

  2. Cardiopulmonary Research Science and Technology Institute, 7777 Forest Lane, Suite C-742, Dallas, TX, 75230, USA

    Elizabeth M. Holper

Authors
  1. Michael Luna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth M. Holper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth M. Holper.

Additional information

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luna, M., Holper, E.M. Use of Novel Antiplatelet Agents in Acute Coronary Syndromes. Curr Atheroscler Rep 17, 12 (2015). https://doi.org/10.1007/s11883-014-0483-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-014-0483-4

Keywords

Search

Navigation